One of the earliest efforts to correct FRDA pathology using a gene therapy approach is the utilization of engineered nucleases to specifically target and excise the pathological expanded GAA repeat in the FXN intron 1 region. The gene discussed is FXN; the disease is Friedreich ataxia.